Rhoen Klinikum AGWBO:RHK +7.69%74 EBITDA Margin % is 7.28% as of Mar. 2026, which is 7% below its 10-year median of 7.83. GuruFocus rates WBO:RHK with a GF Score™ of 74/100 and a GF Value™ of €13.49. The stock has 3 warning signs investors should review. Among 666 Healthcare Providers & Services companies, Rhoen Klinikum AG ranks worse than 59.91% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Rhoen Klinikum AG's EBITDA for the
three
months ended in Mar. 2026 was €32 Mil. Rhoen Klinikum AG's Revenue for the
three
months ended in Mar. 2026 was €436 Mil. Therefore, Rhoen Klinikum AG's EBITDA margin for the quarter that ended in Mar. 2026 was 7.28%.
Rhoen Klinikum AG (WBO:RHK) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Rhoen Klinikum AG EBITDA Margin % Related Terms
Rhoen Klinikum AG EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Rhoen Klinikum AG's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:RHK vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Rhoen Klinikum AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rhoen Klinikum AG EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Rhoen Klinikum AG's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Rhoen Klinikum AG's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rhoen Klinikum AG (WBO:RHK) has a EBITDA Margin % of 7.28% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Rhoen Klinikum AG and its competitors. This is near median its historical median of 7.83. Over the past decade, Rhoen Klinikum AG's EBITDA Margin % has ranged from 5.96 to 13.42. According to the industry distribution chart, Rhoen Klinikum AG ranks #399 out of 666 companies in the Healthcare Providers & Services industry, placing it in the top 59.9%.
Is Rhoen Klinikum AG's EBITDA Margin % too high?
Rhoen Klinikum AG's current EBITDA Margin % of 7.28% is near median its 10-year median of 7.83. Over the past 10 years, this metric has ranged from a low of 5.96 to a high of 13.42. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Rhoen Klinikum AG's value of 7.28% is 28.7% below this industry median. Based on the distribution chart, Rhoen Klinikum AG ranks #399 out of 666 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Rhoen Klinikum AG has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Rhoen Klinikum AG's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Rhoen Klinikum AG ranks #399 out of 666 companies for EBITDA Margin %. This places Rhoen Klinikum AG in the lower half of its industry. The industry median EBITDA Margin % is 10.21. Rhoen Klinikum AG's value of 7.28% is 28.7% below this benchmark. Historically, Rhoen Klinikum AG's own EBITDA Margin % has ranged from 5.96 to 13.42 over the past decade. While the company's 10-year median is 7.83 vs. the industry median of 10.21, Rhoen Klinikum AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 666 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rhoen Klinikum AG's current EBITDA Margin % of 7.28% is 28.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Rhoen Klinikum AG and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rhoen Klinikum AG's current EBITDA Margin % is 7.28%, which is near median its own 10-year median of 7.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhoen Klinikum AG stock overvalued right now?
Rhoen Klinikum AG (WBO:RHK) has a current EBITDA Margin % of 7.28%. The stock's GF Value™ is €13.49, compared to a current price of €14.00 — trading 3.8% above its estimated fair value. The current EBITDA Margin % is 7.28%, which is near median its 10-year median of 7.83 and 28.7% below the Healthcare Providers & Services industry median of 10.21. Rhoen Klinikum AG's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Rhoen Klinikum AG (WBO:RHK), the current EBITDA Margin % is 7.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rhoen Klinikum AG (WBO:RHK) Overvalued in 2026?
Based on GuruFocus' analysis, Rhoen Klinikum AG stock appears to be overvalued.
The current stock price of €14.00 is trading 3.8% above its estimated GF Value™ of €13.49.
Key valuation signals for WBO:RHK:
EBITDA Margin %: 7.28% (near median its 10-year median of 7.83)
GF Value™: €13.49 vs. price of €14.00 (3.8% above fair value)
Industry Position: 28.7% below the Healthcare Providers & Services median (#399 of 666)
No single metric tells the full story. See the WBO:RHK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rhoen Klinikum AG provides medical care and healthcare services. The firm operates in three business areas: acute hospitals, medical care centers, and rehabilitation hospitals. The acute hospitals business contributes to the vast majority of the firm's overall revenue. The majority of patients at the firm's acute hospitals and medical care centers are treated on inpatient, semi-inpatient and outpatient healthcare basis. The company generates the entire revenue in Germany, with the Bavaria and Hesse regions contributing the majority proportions of revenue.
74GF Score
Get the complete analysis for WBO:RHK
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:RHK has been successfully added to your 
